MSN 571 Final Exam-with 2026- 2026 11pages

1) A 40-year old female patient is being followed up for diabetes mellitus. She is currently on Metformin 1 gram twice a day and has been tolerating it well for about six months. Her hemoglobin A1c a week ago was 8.9%. The plan is to initiate liraglutide therapy in addition to the metformin. Which of the following statements is true with regards to liraglutide. â–ª Liraglutide may be stored in the refrigerator or freezer prior to first use. â–ª The brand name is Bydureon â–ª Nausea and/or vomiting are common side effects of therapy â–ª It should be administered intramuscularly into the upper arm. 2) The patient who takes insulin has just been prescribed a beta blocker drug. You recognize that the interaction of the beta blocker and the insulin may have which result? â–ª Decreased activity of the beta blocker drug â–ª Enhanced activity of the beta blocker drug â–ª Masked signs of hypoglycemia â–ª Masked signs of hyperglycemia 3) The drug of choice for type 2 diabetics is metformin. Metformin: â–ª Increases intestinal uptake of glucose â–ª Decreases glycogenolysis by the liver â–ª Increases the release of insulin from beta cells â–ª Prevents weight gain associated with hyperglycemia 4) Which classification of oral hypoglycemic drugs decreases hepatic glucose production and increases insulin sensitivity and peripheral glucose uptake? â–ª Sulfonylureas (glyburide) â–ª Meglitinides (glinides) â–ª Biguanide (metformin) â–ª alpha-glycosidase inhibitor (miglitol) 5) A breast-feeding mother is seen in your clinic wanting contraceptive and plans on breast-feeding for a year. What is an inappropriate choice for this patient? â–ª Depo-Provera 150mg IM every 3 months â–ª Progestin-only OC â–ª Combination OC â–ª Intrauterine device 6) Which of the following is (are) true about oral contraceptives (OCs)? â–ª Estrostep, Ortho Tri-Cyclen, Beyaz, and YAZ are approved for managing acne in women â–ª All the answrs are correct â–ª OCs favorably affect menstrual symptoms: cramps reduction, reduced menstrual flow volume and duration. â–ª OCs decrease the risk for several disorders, including ovarian cancer, endometrial cancer, ovarian cysts, pelvic inflammatory disease, benign breast disease.